^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227
Published date:
05/16/2018
Excerpt:
Contradicting evidence: PFS was improved with nivo + chemo vs chemo (HR = 0.74 [95% CI: 0.58, 0.94]; minimum follow-up 11.2 mo....1L nivo + chemo improved PFS vs chemo in pts with advanced NSCLC and < 1% tumor PD-L1 expression, and was well tolerated.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2018.36.15_suppl.9001
Trial ID:
Source:
Title:
Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).
Published date:
05/28/2020
Excerpt:
...results were found for PEG+N versus N: ORR 14.8% v. 12.0%, mPFS 1.9 v. 1.9 months with HR = 1.01 (95% CI [0.52, 1.95]), mOS 6.7 v. 10.7 months with HR = 1.87 (95% CI [0.77, 4.53])...adding PEG to N did not lead to improvement in ORR, PFS, or OS in post-platinum advanced NSCLC with no or low PD-L1 expression.
DOI:
10.1200/JCO.2020.38.15_suppl.e21744
Trial ID:
